{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"The proportion of patients who are progression-free at 6 months is calculated by dividing the number of evaluable participants who are progression-free at 6 months based on the Response Evaluation Criteria for Solid Tumors (RECIST) by the total number of evaluable participants.","groups":[{"description":"Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I"}],"paramType":"NUMBER","populationDescription":"All 34 participants were analyzed for this endpoint.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}